Cargando…

A Strategy to Employ Clitoria ternatea as a Prospective Brain Drug Confronting Monoamine Oxidase (MAO) Against Neurodegenerative Diseases and Depression

ABSTRACT: Ayurveda is a renowned traditional medicine practiced in India from ancient times and Clitoria ternatea is one such prospective medicinal herb incorporated as an essential constituent in a brain tonic called as medhya rasayan for treating neurological disorders. This work emphasises the si...

Descripción completa

Detalles Bibliográficos
Autores principales: Margret, A. Anita, Begum, T. Nargis, Parthasarathy, S., Suvaithenamudhan, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4681707/
https://www.ncbi.nlm.nih.gov/pubmed/26667936
http://dx.doi.org/10.1007/s13659-015-0079-x
_version_ 1782405759953272832
author Margret, A. Anita
Begum, T. Nargis
Parthasarathy, S.
Suvaithenamudhan, S.
author_facet Margret, A. Anita
Begum, T. Nargis
Parthasarathy, S.
Suvaithenamudhan, S.
author_sort Margret, A. Anita
collection PubMed
description ABSTRACT: Ayurveda is a renowned traditional medicine practiced in India from ancient times and Clitoria ternatea is one such prospective medicinal herb incorporated as an essential constituent in a brain tonic called as medhya rasayan for treating neurological disorders. This work emphasises the significance of the plant as a brain drug there by upholding Indian medicine. The phytochemicals from the root extract were extricated using gas chromatography–mass spectrometry assay and molecular docking against the protein Monoamine oxidase was performed with four potential compounds along with four reference compounds of the plant. This persuades the prospect of C. ternatea as a remedy for neurodegenerative diseases and depression. The in silico assay enumerates that a major compound (Z)-9,17-octadecadienal obtained from the chromatogram with a elevated retention time of 32.99 furnished a minimum binding affinity energy value of −6.5 kcal/mol against monoamine oxidase (MAO-A). The interactions with the amino acid residues ALA 68, TYR 60 and TYR 69 were analogous to the reference compound kaempferol-3-monoglucoside with a least score of −13.90/−12.95 kcal/mol against the isoforms (MAO) A and B. This study fortifies the phytocompounds of C. ternatea as MAO-inhibitors and to acquire a pharmaceutical approach in rejuvenating Ayurvedic medicine. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-4681707
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-46817072015-12-22 A Strategy to Employ Clitoria ternatea as a Prospective Brain Drug Confronting Monoamine Oxidase (MAO) Against Neurodegenerative Diseases and Depression Margret, A. Anita Begum, T. Nargis Parthasarathy, S. Suvaithenamudhan, S. Nat Prod Bioprospect Original Article ABSTRACT: Ayurveda is a renowned traditional medicine practiced in India from ancient times and Clitoria ternatea is one such prospective medicinal herb incorporated as an essential constituent in a brain tonic called as medhya rasayan for treating neurological disorders. This work emphasises the significance of the plant as a brain drug there by upholding Indian medicine. The phytochemicals from the root extract were extricated using gas chromatography–mass spectrometry assay and molecular docking against the protein Monoamine oxidase was performed with four potential compounds along with four reference compounds of the plant. This persuades the prospect of C. ternatea as a remedy for neurodegenerative diseases and depression. The in silico assay enumerates that a major compound (Z)-9,17-octadecadienal obtained from the chromatogram with a elevated retention time of 32.99 furnished a minimum binding affinity energy value of −6.5 kcal/mol against monoamine oxidase (MAO-A). The interactions with the amino acid residues ALA 68, TYR 60 and TYR 69 were analogous to the reference compound kaempferol-3-monoglucoside with a least score of −13.90/−12.95 kcal/mol against the isoforms (MAO) A and B. This study fortifies the phytocompounds of C. ternatea as MAO-inhibitors and to acquire a pharmaceutical approach in rejuvenating Ayurvedic medicine. GRAPHICAL ABSTRACT: [Image: see text] Springer Berlin Heidelberg 2015-12-14 /pmc/articles/PMC4681707/ /pubmed/26667936 http://dx.doi.org/10.1007/s13659-015-0079-x Text en © The Author(s) 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Margret, A. Anita
Begum, T. Nargis
Parthasarathy, S.
Suvaithenamudhan, S.
A Strategy to Employ Clitoria ternatea as a Prospective Brain Drug Confronting Monoamine Oxidase (MAO) Against Neurodegenerative Diseases and Depression
title A Strategy to Employ Clitoria ternatea as a Prospective Brain Drug Confronting Monoamine Oxidase (MAO) Against Neurodegenerative Diseases and Depression
title_full A Strategy to Employ Clitoria ternatea as a Prospective Brain Drug Confronting Monoamine Oxidase (MAO) Against Neurodegenerative Diseases and Depression
title_fullStr A Strategy to Employ Clitoria ternatea as a Prospective Brain Drug Confronting Monoamine Oxidase (MAO) Against Neurodegenerative Diseases and Depression
title_full_unstemmed A Strategy to Employ Clitoria ternatea as a Prospective Brain Drug Confronting Monoamine Oxidase (MAO) Against Neurodegenerative Diseases and Depression
title_short A Strategy to Employ Clitoria ternatea as a Prospective Brain Drug Confronting Monoamine Oxidase (MAO) Against Neurodegenerative Diseases and Depression
title_sort strategy to employ clitoria ternatea as a prospective brain drug confronting monoamine oxidase (mao) against neurodegenerative diseases and depression
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4681707/
https://www.ncbi.nlm.nih.gov/pubmed/26667936
http://dx.doi.org/10.1007/s13659-015-0079-x
work_keys_str_mv AT margretaanita astrategytoemployclitoriaternateaasaprospectivebraindrugconfrontingmonoamineoxidasemaoagainstneurodegenerativediseasesanddepression
AT begumtnargis astrategytoemployclitoriaternateaasaprospectivebraindrugconfrontingmonoamineoxidasemaoagainstneurodegenerativediseasesanddepression
AT parthasarathys astrategytoemployclitoriaternateaasaprospectivebraindrugconfrontingmonoamineoxidasemaoagainstneurodegenerativediseasesanddepression
AT suvaithenamudhans astrategytoemployclitoriaternateaasaprospectivebraindrugconfrontingmonoamineoxidasemaoagainstneurodegenerativediseasesanddepression
AT margretaanita strategytoemployclitoriaternateaasaprospectivebraindrugconfrontingmonoamineoxidasemaoagainstneurodegenerativediseasesanddepression
AT begumtnargis strategytoemployclitoriaternateaasaprospectivebraindrugconfrontingmonoamineoxidasemaoagainstneurodegenerativediseasesanddepression
AT parthasarathys strategytoemployclitoriaternateaasaprospectivebraindrugconfrontingmonoamineoxidasemaoagainstneurodegenerativediseasesanddepression
AT suvaithenamudhans strategytoemployclitoriaternateaasaprospectivebraindrugconfrontingmonoamineoxidasemaoagainstneurodegenerativediseasesanddepression